←Back to Expert Scholars
Translational Medicine / 转化医学Nivolumab Lung Cancer Trials
Mark Awad
MD, PhD
🏢Dana-Farber Cancer Institute🌐USA
Clinical Director, Thoracic Oncology
65
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Mark Awad has led neoadjuvant and adjuvant nivolumab trials in resectable non-small cell lung cancer and studies molecular predictors of immunotherapy response such as STK11 and KEAP1 mutations. He is clinical director of thoracic oncology at Dana-Farber.
Share:
🧪Research Fields 研究领域
NSCLC immunotherapy
nivolumab neoadjuvant
STK11 KEAP1 mutations
tumor mutation burden
lung cancer translational
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Mark Awad 的研究动态
Follow Mark Awad's research updates
留下邮箱，当我们发布与 Mark Awad（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment